Using flecainide to treat frequent premature ventricular contractions and related heart issues
Official title: UNIFLECA Study: Prospective Cohort Study on Flecainide's Impact on Persistent High Premature Ventricular Contraction Burden and PVC-Induced Cardiomyopathy
Run by University of Athens · NCT06949748 · Data updated 2026-11-12
This study is testing if the heart medication flecainide can help adults with frequent heartbeats and related heart issues who can't or don't want to have a procedure called catheter ablation.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | University of Athens Academic / other |
| Locations | 6 sites (Pátrai, Achaia and 5 other locations) |
| Status | Recruiting |
| Started | April 26, 2024 |
| Main results expected | July 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | July 2, 2025 |
| Trial ID | NCT06949748 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with frequent idiopathic PVCs and structurally normal hearts who have declined or are ineligible for catheter ablation.
✕Probably not a fit
Patients with structural heart disease, ischemic heart disease, or significant ventricular arrhythmias are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The UNIFLECA study is an observational cohort that evaluates the efficacy, safety, and tolerability of flecainide in adults experiencing frequent idiopathic premature ventricular contractions (PVCs) and suspected PVC-induced cardiomyopathy. Participants undergo thorough cardiac evaluations, including echocardiography and cardiac MRI, to confirm the absence of structural heart disease. Flecainide is administered as monotherapy, starting at a dose of 100 mg/day and potentially increasing to 200 mg/day based on clinical response and ECG findings. This study specifically targets patients who are ineligible or unwilling to undergo catheter ablation.
Why it matters
Potential benefit: If successful, this study could provide an effective treatment option for patients suffering from PVC-induced cardiomyopathy, potentially reversing left ventricular dysfunction.
How similar studies have gone: While the use of flecainide for PVCs is established, this specific approach in a cohort with PVC-induced cardiomyopathy is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Frequent idiopathic PVCs (burden \>5% on multiple 24-hour Holter ECG recordings) * Normal cardiac structure and function on echocardiography * No late gadolinium enhancement or myocardial scar on cardiac MRI * Normal coronary angiography (excluding ischemic cardiomyopathy) * Normal serum electrolytes and renal function * Willingness to comply with follow-up schedule and drug titration Exclusion Criteria: * Structural heart disease * Ischemic heart disease (confirmed by angiography) * History of sustained ventricular arrhythmias * Left ventricular ejection fraction (LVEF) \<40% at baseline * Brugada syndrome, long QT syndrome, or other channelopathies * Contraindications to class IC agents * Use of concurrent antiarrhythmics or proarrhythmic drugs
Where it's running
-
Cardiology Clinic, University Hospital of Patras
Pátrai, Achaia, Greece Recruiting -
1st Cardiology Clinic, National and Kapodistrian University of Athens
Athens, Attica, Greece Recruiting -
Cardilogy Clinic, University of Crete
Heraklion, Greece Recruiting -
2nd Cardiology Clinic, University of Ioannina
Ioannina, Greece Active not recruiting -
2nd Cardiology Clinic, Aristotle University of Thessaloniki
Thessaloniki, Greece Active not recruiting -
3rd Cardiology Clinic, Aristotle University of Thessaloniki
Thessaloniki, Greece Active not recruiting
Study contacts
- Study coordinator: Dimitrios Tsiachris, MD, PhD
- Email: dtsiachris@yahoo.com
- Phone: +306944849926
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Catheter ablation vs. anti-arrhythmic drugs for PVCs
This study tests whether catheter ablation or anti-arrhythmic medications are better at reducing PVC symptoms and improving quality of life for adults with a normal heart function.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Severe Complications During VT/PVC Ablation
This study looks at real-world cases to see what severe complications occur during VT or PVC ablations and how patients are managed afterward.
-
Liver and Coagulation Markers in ATTR Cardiac Amyloidosis
This study tests liver function and blood-clotting markers in people with ATTR-CA to see if they reflect disease severity and progression.
-
Stepwise withdrawal of ARNI and SGLT2i in HF with normalized ejection fraction
This trial tests whether gradually stopping ARNI and SGLT2i is safe for people whose heart function has recovered after fixing a reversible heart‑disease cause.
-
RHYthm and Myocardial Function Relationship in Heart Disease
This study tests how heart rhythm patterns relate to heart muscle function in adults with arrhythmias or cardiomyopathy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.